Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with mirabegron may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2D6. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by mirabegron. In 12 healthy male volunteers, administration of a single 100 mg oral dose of metoprolol following pretreatment with immediate-release mirabegron 160 mg orally once daily for 5 days increased the metoprolol peak plasma concentration (Cmax) by 90% and systemic exposure (AUC) by 229% compared to administration of metoprolol alone. Likewise, in 28 healthy male and female volunteers, Cmax of desipramine increased by 79% and AUC increased by 241% when a single 50 mg oral dose of desipramine was administered after multiple-dose administration of extended-release mirabegron 100 mg once daily for 18 days.

MANAGEMENT: Caution is advised if mirabegron must be used concomitantly with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mirabegron is added to or withdrawn from therapy.

Information for this minor interaction is available on the professional version.